CO4480020A1 - Formulaciones farmaceuticas - Google Patents
Formulaciones farmaceuticasInfo
- Publication number
- CO4480020A1 CO4480020A1 CO96061449A CO96061449A CO4480020A1 CO 4480020 A1 CO4480020 A1 CO 4480020A1 CO 96061449 A CO96061449 A CO 96061449A CO 96061449 A CO96061449 A CO 96061449A CO 4480020 A1 CO4480020 A1 CO 4480020A1
- Authority
- CO
- Colombia
- Prior art keywords
- formulation according
- active drug
- molecular weight
- aqueous media
- active
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9523752.5A GB9523752D0 (en) | 1995-11-21 | 1995-11-21 | Pharmaceutical formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
CO4480020A1 true CO4480020A1 (es) | 1997-07-09 |
Family
ID=10784188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO96061449A CO4480020A1 (es) | 1995-11-21 | 1996-11-21 | Formulaciones farmaceuticas |
Country Status (29)
Country | Link |
---|---|
EP (1) | EP0862437A1 (is) |
JP (1) | JPH10513481A (is) |
KR (1) | KR19990071505A (is) |
CN (1) | CN1215993A (is) |
AP (1) | AP718A (is) |
AR (1) | AR004335A1 (is) |
AU (1) | AU709560B2 (is) |
BG (1) | BG102438A (is) |
BR (1) | BR9611626A (is) |
CA (1) | CA2232715A1 (is) |
CO (1) | CO4480020A1 (is) |
CZ (1) | CZ155498A3 (is) |
GB (1) | GB9523752D0 (is) |
HR (1) | HRP960554A2 (is) |
HU (1) | HUP9903734A3 (is) |
IS (1) | IS4706A (is) |
MA (1) | MA26410A1 (is) |
MX (1) | MX9804008A (is) |
NO (1) | NO982302L (is) |
NZ (1) | NZ322053A (is) |
OA (1) | OA10687A (is) |
PE (1) | PE22898A1 (is) |
PL (1) | PL326981A1 (is) |
SK (1) | SK63098A3 (is) |
TN (1) | TNSN96141A1 (is) |
TR (1) | TR199800902T2 (is) |
WO (1) | WO1997018814A1 (is) |
YU (1) | YU62096A (is) |
ZA (1) | ZA969722B (is) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2258300T3 (es) * | 1997-12-16 | 2006-08-16 | Pfizer Products Inc. | Combinacion de antagonistas del receptor alfa-1-adrenergico y un inhibidor gmpc pdev para el tratamiento de la impotencia. |
CA2320900C (en) | 1998-03-19 | 2009-10-27 | Bristol-Myers Squibb Company | Biphasic controlled release delivery system for high solubility pharmaceuticals and method |
GT199900061A (es) * | 1998-05-15 | 2000-10-14 | Pfizer | Formulaciones farmaceuticas. |
EP0987020A1 (en) * | 1998-09-04 | 2000-03-22 | Pharma Pass LLC | Metoprolol composition and processes for manufacturing the same |
EP0974343B1 (en) * | 1998-07-22 | 2004-09-29 | Pharma Pass II LLC | Process for manufacturing a solid metoprolol composition |
CO5140079A1 (es) * | 1998-10-14 | 2002-03-22 | Novartis Ag | Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo |
UA67802C2 (uk) | 1998-10-23 | 2004-07-15 | Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. | Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції |
US20030059467A1 (en) * | 2001-09-14 | 2003-03-27 | Pawan Seth | Pharmaceutical composition comprising doxasozin |
TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
US6723340B2 (en) * | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
US7612112B2 (en) | 2001-10-25 | 2009-11-03 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
US8329217B2 (en) | 2001-11-06 | 2012-12-11 | Osmotica Kereskedelmi Es Szolgaltato Kft | Dual controlled release dosage form |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
WO2005037247A2 (en) * | 2003-10-17 | 2005-04-28 | Ranbaxy Laboratories Limited | Oral matrix formulations of doxazosin |
US20050255157A1 (en) * | 2004-05-11 | 2005-11-17 | Glenmark Pharmaceuticals Limited | Sustained release, mucoadhesive vaginal pharmaceutical compositions |
KR100574554B1 (ko) * | 2004-05-28 | 2006-04-27 | 한미약품 주식회사 | 니아신의 경구투여용 서방성 조성물 |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
KR100679111B1 (ko) * | 2004-11-20 | 2007-02-07 | 대우약품공업주식회사 | 독사조신을 포함하는 서방성 정제 |
CN102198273A (zh) * | 2005-08-22 | 2011-09-28 | 诺瓦提斯公司 | 包含pH依赖性药物、pH调节剂和阻滞剂的药物组合物 |
US20090176882A1 (en) | 2008-12-09 | 2009-07-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
DE602007012236D1 (de) | 2006-04-26 | 2011-03-10 | Supernus Pharmaceuticals Inc | Oxcarbazepin-zubereitungen für kontrollierte freisetzung mit sigmoidalem freisetzungsprofil |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
EA030606B1 (ru) | 2006-05-04 | 2018-08-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Способы приготовления лекарственного средства, содержащего полиморфы |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
CN100396282C (zh) * | 2006-07-25 | 2008-06-25 | 山东省医药工业研究所 | 甲磺酸多沙唑嗪缓释胶囊及制备方法 |
SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
US8372432B2 (en) | 2008-03-11 | 2013-02-12 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
WO2009114648A1 (en) | 2008-03-11 | 2009-09-17 | Depomed Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
KR101004205B1 (ko) | 2008-12-17 | 2010-12-24 | 동아제약주식회사 | 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물 |
WO2010092125A1 (en) | 2009-02-13 | 2010-08-19 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof |
US8828953B2 (en) | 2009-04-20 | 2014-09-09 | NaZura BioHealth, Inc. | Chemosensory receptor ligand-based therapies |
EA201101524A1 (ru) | 2009-04-20 | 2012-07-30 | Элселикс Терапьютикс, Инк. | Способ и композиция для лечения состояния, связанного с хемосенсорным рецептором |
US9901551B2 (en) | 2009-04-20 | 2018-02-27 | Ambra Bioscience Llc | Chemosensory receptor ligand-based therapies |
BR112012012641A2 (pt) | 2009-11-27 | 2020-08-11 | Boehringer Ingelheim International Gmbh | TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA |
US20110150989A1 (en) * | 2009-12-22 | 2011-06-23 | Mallinkckrodt Inc. | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans |
US9198861B2 (en) | 2009-12-22 | 2015-12-01 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
WO2011138421A1 (en) | 2010-05-05 | 2011-11-10 | Boehringer Ingelheim International Gmbh | Combination therapy |
MX342120B (es) | 2010-07-09 | 2016-09-14 | William Owen Wilkison | Combinación de sistema de liberación prolongada/inmediata para productos farmacéuticos de vida media corta como el remogliflozin. |
CA2815024A1 (en) | 2010-10-19 | 2012-04-26 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
CA2823397C (en) | 2011-01-07 | 2020-03-10 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
CN102058555A (zh) * | 2011-01-13 | 2011-05-18 | 北京汇诚瑞祥医药技术有限公司 | 一种多沙唑嗪控释片 |
AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
CN102188431A (zh) * | 2011-05-09 | 2011-09-21 | 浙江九旭药业有限公司 | 甲磺酸多沙唑嗪缓释片及其制备方法 |
US9050335B1 (en) | 2011-05-17 | 2015-06-09 | Mallinckrodt Llc | Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia |
US8858963B1 (en) | 2011-05-17 | 2014-10-14 | Mallinckrodt Llc | Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia |
US8741885B1 (en) | 2011-05-17 | 2014-06-03 | Mallinckrodt Llc | Gastric retentive extended release pharmaceutical compositions |
US20130143867A1 (en) | 2011-12-02 | 2013-06-06 | Sychroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
WO2013158928A2 (en) | 2012-04-18 | 2013-10-24 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
EP3003297A4 (en) | 2013-06-05 | 2017-04-19 | Synchroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
ES2950384T3 (es) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Uso médico de un inhibidor de DPP-4 |
CN105616378A (zh) * | 2014-10-31 | 2016-06-01 | 康普药业股份有限公司 | 一种氟康唑胶囊及其制备方法 |
EP3468562A1 (en) | 2016-06-10 | 2019-04-17 | Boehringer Ingelheim International GmbH | Combinations of linagliptin and metformin |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1198386B (it) * | 1982-07-06 | 1988-12-21 | Lepetit Spa | Un prodotto a rilascio protratto contenente il suloctidile |
US4765989A (en) * | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
US4837111A (en) * | 1988-03-21 | 1989-06-06 | Alza Corporation | Dosage form for dispensing drug for human therapy |
IL92966A (en) * | 1989-01-12 | 1995-07-31 | Pfizer | Hydrogel-operated release devices |
ZA915648B (en) * | 1990-07-23 | 1992-05-27 | Alza Corp | Oral osmotic device for delivering nicotine |
-
1995
- 1995-11-21 GB GBGB9523752.5A patent/GB9523752D0/en active Pending
-
1996
- 1996-11-11 PL PL96326981A patent/PL326981A1/xx unknown
- 1996-11-11 TR TR1998/00902T patent/TR199800902T2/xx unknown
- 1996-11-11 HU HU9903734A patent/HUP9903734A3/hu unknown
- 1996-11-11 SK SK630-98A patent/SK63098A3/sk unknown
- 1996-11-11 AU AU75721/96A patent/AU709560B2/en not_active Ceased
- 1996-11-11 NZ NZ322053A patent/NZ322053A/xx unknown
- 1996-11-11 EP EP96938215A patent/EP0862437A1/en not_active Withdrawn
- 1996-11-11 KR KR1019980703777A patent/KR19990071505A/ko not_active Application Discontinuation
- 1996-11-11 JP JP9519364A patent/JPH10513481A/ja active Pending
- 1996-11-11 WO PCT/EP1996/005020 patent/WO1997018814A1/en not_active Application Discontinuation
- 1996-11-11 CZ CZ981554A patent/CZ155498A3/cs unknown
- 1996-11-11 BR BR9611626A patent/BR9611626A/pt not_active Application Discontinuation
- 1996-11-11 CN CN96198486A patent/CN1215993A/zh active Pending
- 1996-11-11 CA CA002232715A patent/CA2232715A1/en not_active Abandoned
- 1996-11-20 PE PE1996000831A patent/PE22898A1/es not_active Application Discontinuation
- 1996-11-20 YU YU62096A patent/YU62096A/sh unknown
- 1996-11-20 MA MA24397A patent/MA26410A1/fr unknown
- 1996-11-20 AR ARP960105252A patent/AR004335A1/es unknown
- 1996-11-20 ZA ZA9609722A patent/ZA969722B/xx unknown
- 1996-11-20 TN TNTNSN96141A patent/TNSN96141A1/fr unknown
- 1996-11-21 HR HR9523752.5A patent/HRP960554A2/hr not_active Application Discontinuation
- 1996-11-21 AP APAP/P/1996/000883A patent/AP718A/en active
- 1996-11-21 CO CO96061449A patent/CO4480020A1/es unknown
-
1998
- 1998-03-31 IS IS4706A patent/IS4706A/is unknown
- 1998-05-08 BG BG102438A patent/BG102438A/xx unknown
- 1998-05-19 OA OA9800058A patent/OA10687A/en unknown
- 1998-05-20 MX MX9804008A patent/MX9804008A/es unknown
- 1998-05-20 NO NO982302A patent/NO982302L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MX9804008A (es) | 1998-09-30 |
MA26410A1 (fr) | 2004-12-20 |
AU7572196A (en) | 1997-06-11 |
AR004335A1 (es) | 1998-11-04 |
OA10687A (en) | 2002-11-27 |
BR9611626A (pt) | 1999-06-01 |
NZ322053A (en) | 1999-11-29 |
PE22898A1 (es) | 1998-05-07 |
AU709560B2 (en) | 1999-09-02 |
BG102438A (en) | 1999-01-29 |
NO982302L (no) | 1998-07-17 |
CA2232715A1 (en) | 1997-05-29 |
IS4706A (is) | 1998-03-31 |
SK63098A3 (en) | 1999-05-07 |
HRP960554A2 (en) | 1998-02-28 |
ZA969722B (en) | 1998-05-20 |
TNSN96141A1 (fr) | 2005-03-15 |
TR199800902T2 (xx) | 1998-09-21 |
KR19990071505A (ko) | 1999-09-27 |
AP9600883A0 (en) | 1997-01-31 |
HUP9903734A2 (hu) | 2000-03-28 |
EP0862437A1 (en) | 1998-09-09 |
JPH10513481A (ja) | 1998-12-22 |
PL326981A1 (en) | 1998-11-09 |
HUP9903734A3 (en) | 2000-04-28 |
YU62096A (sh) | 1999-03-04 |
AP718A (en) | 1999-01-06 |
CN1215993A (zh) | 1999-05-05 |
NO982302D0 (no) | 1998-05-20 |
CZ155498A3 (cs) | 1999-03-17 |
WO1997018814A1 (en) | 1997-05-29 |
GB9523752D0 (en) | 1996-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO4480020A1 (es) | Formulaciones farmaceuticas | |
AR039744A1 (es) | Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada | |
AR030541A1 (es) | Acidos aminopropilfosfinicos, su utilizacion para la manufactura de medicamentos, y formulacion farmaceutica | |
AR065073A2 (es) | Una formulacion medicamentosa de sistema de matriz que tiene liberacion controlada de un compuesto activo | |
AR008878A1 (es) | Antagonistas del receptor de vitronectina, un metodo para su preparacion, una composicion farmaceutica que los contiene y el uso de las mismas para la preparacion de un medicamento. | |
CO5640072A2 (es) | Composiciones farmaceuticas que comprenden atorvastatina fabricada sin granulacion | |
CY1107675T1 (el) | Φαρμακευτικα αλατα τραμαδολης | |
AR040722A1 (es) | Formulaciones y formas de dosificacion para la administracion controlada de topiramato | |
AR006678A1 (es) | Derivados de macrolidas triciclicas, una composicion farmaceutica que los contiene, uso de los mismos para preparar medicamentos y procedimientopara su preparacion | |
PA8548701A1 (es) | Azaindoles | |
CY1105648T1 (el) | Filbanserin για την θεραπεια εξτραπυραμιδικων διαταραχων κινησης | |
SV1999000152A (es) | Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial | |
BRPI0418026A (pt) | derivados de fenilalanina ou sais farmaceuticamente aceitáveis destes, composição farmacêutica, antagonista de alfa4 integrina, e, agente terapêutico ou agente preventivo para doenças | |
CO5160287A1 (es) | Formulacion de liberacion controlada de divalproex sodico | |
CY1106137T1 (el) | Φαρμακευτικη συνθεση πepιλαμβανουσα λουμιρακοξιμπη | |
ATE292453T1 (de) | Antivirale arznei | |
AR011919A1 (es) | FORMULACIoN EN COMPRIMIDOS O CÁPSULAS PARA TRAGAR DE PARACETAMOL (N-ACETIL-P-AMINOFENOL) Y PROCEDIMIENTO PARA PREPARARLA | |
NO962752L (no) | Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose | |
PE20030830A1 (es) | Ambroxol para el tratamiento de estados dolorosos en la cavidad bucal y faringea | |
UY27539A1 (es) | Formulación farmacéutica | |
BR9809708A (pt) | Composições farmacêuticas de peptìdeos tendo solubilidade baixa em meio fisiológico | |
ES2194618T1 (es) | Composicion oralmente desintegrable que comprende mirtazapina. | |
JP2003055258A (ja) | 安定化された組成物 | |
AR035006A1 (es) | Derivado de naftiridin-dibenzo[a,d]ciclohepteno-10-acetico, composicion farmaceutica, y el uso de dicho derivado para la fabricacion de un medicamento. | |
JP2003055223A (ja) | 安定化された組成物 |